{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:03:07Z","timestamp":1780718587408,"version":"3.54.1"},"reference-count":27,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.5551\/jat.65984","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:08:22Z","timestamp":1770415702000},"page":"759-774","source":"Crossref","is-referenced-by-count":0,"title":["The Effects of Pemafibrate on Fibrinogen and Thrombogenicity in Patients with Coronary Artery Disease"],"prefix":"10.5551","volume":"33","author":[{"given":"Masanobu","family":"Ishii","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"},{"name":"Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Fujisue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Yamanaga","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kumamoto Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Hanatani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Matsuzawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukuoka Tokushukai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukuoka Tokushukai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukuoka Tokushukai Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Takae","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Miyazaki Prefectural Nobeoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Shirahama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyasu","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Miyazaki Prefectural Nobeoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Japanese Red Cross Kumamoto Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Japanese Red Cross Kumamoto Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Horio","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saiseikai Kumamoto Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saiseikai Kumamoto Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Rokutanda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kumamoto Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Morihisa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kumamoto Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuo","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kumamoto Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunosuke","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of PEMA-TAS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Bor\u00e9n J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokg\u00f6zoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ and Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2017; 38: 2459-2472","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Raposeiras-Roubin S, Rossell\u00f3 X, Oliva B, Fern\u00e1ndez-Friera L, Mendiguren JM, Andr\u00e9s V, Bueno H, Sanz J, Mart\u00ednez de Vega V, Abu-Assi E, I\u00f1iguez A, Fern\u00e1ndez-Ortiz A, Ib\u00e1\u00f1ez B and Fuster V. Triglycerides and Residual Atherosclerotic Risk. J Am Coll Cardiol, 2021; 77: 3031-3041","DOI":"10.1016\/j.jacc.2021.04.059"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Fujiyoshi A, Kohsaka S, Hata J, Hara M, Kai H, Masuda D, Miyamatsu N, Nishio Y, Ogura M, Sata M, Sekiguchi K, Takeya Y, Tamura K, Wakatsuki A, Yoshida H, Fujioka Y, Fukazawa R, Hamada O, Higashiyama A, Kabayama M, Kanaoka K, Kawaguchi K, Kosaka S, Kunimura A, Miyazaki A, Nii M, Sawano M, Terauchi M, Yagi S, Akasaka T, Minamino T, Miura K and Node K. JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease. Circ J, 2024; 88: 763-842","DOI":"10.1253\/circj.CJ-23-0285"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A and Yanai H. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853","DOI":"10.5551\/jat.GL2022"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, Coresh J, Guild CS, Boerwinkle E, Ballantyne CM and Hoogeveen RC. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol, 2018; 72: 156-169","DOI":"10.1016\/j.jacc.2018.04.050"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Imano H, Li J, Tanaka M, Yamagishi K, Muraki I, Umesawa M, Kiyama M, Kitamura A, Sato S and Iso H. Optimal Cut-off Points of Nonfasting and Fasting Triglycerides for Prediction of Ischemic Heart Disease in Japanese General Population: The Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb, 2023; 30: 110-130","DOI":"10.5551\/jat.63358"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Higashiyama A, Wakabayashi I, Okamura T, Kokubo Y, Watanabe M, Takegami M, Honda-Kohmo K, Okayama A and Miyamoto Y. The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers: the Suita Study. J Atheroscler Thromb, 2021; 28: 1275-1288","DOI":"10.5551\/jat.62730"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mizuta H, Ishii M, Ikebe S, Otsuka Y, Yamanouchi Y, Nakamura T and Tsujita K. Triglycerides and the Risk of Atherosclerotic Cardiovascular Events Across Different Risk Categories. J Atheroscler Thromb, 2025; 32: 786-803","DOI":"10.5551\/jat.65334"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Maruo T, Ike A, Takamiya Y, Matsuoka Y, Shigemoto E, Kato Y, Kuwano T, Sugihara M, Kawamura A and Miura S-i. Impact of Controlling Serum Low-Density Lipoprotein Cholesterol and Triglycerides on Long-Term Clinical Outcomes in Diabetic Patients Who Have Undergone Percutaneous Coronary Intervention. Circulation Reports, 2024; 6: 573-582","DOI":"10.1253\/circrep.CR-24-0081"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Jr., Cushman WC, Simons-Morton DG and Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1563-1574","DOI":"10.1056\/NEJMoa1001282"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kes\u00e4niemi YA, Sullivan D, Hunt D, Colman P, d\u2019Emden M, Whiting M, Ehnholm C and Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366: 1849-1861","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yamashita S, Masuda D and Matsuzawa Y. Clinical Applications of a Novel Selective PPAR\u03b1 Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases. J Atheroscler Thromb, 2019; 26: 389-402","DOI":"10.5551\/jat.48918"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, P\u00e1ll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P and Ridker PM. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med, 2022; 387: 1923-1934","DOI":"10.1056\/NEJMoa2210645"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kaikita K, Hosokawa K, Dahlen JR and Tsujita K. Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease. Thromb Haemost, 2019; 119: 1554-1562","DOI":"10.1055\/s-0039-1693411"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ito M, Kaikita K, Sueta D, Ishii M, Oimatsu Y, Arima Y, Iwashita S, Takahashi A, Hoshiyama T, Kanazawa H, Sakamoto K, Yamamoto E, Tsujita K, Yamamuro M, Kojima S, Hokimoto S, Yamabe H and Ogawa H. Total Thrombus-Formation Analysis System (T-TAS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc, 2016; 5","DOI":"10.1161\/JAHA.115.002744"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ishii M, Kaikita K, Ito M, Sueta D, Arima Y, Takashio S, Izumiya Y, Yamamoto E, Yamamuro M, Kojima S, Hokimoto S, Yamabe H, Ogawa H and Tsujita K. Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System. Sci Rep, 2017; 7: 7399","DOI":"10.1038\/s41598-017-07939-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Arima Y, Kaikita K, Ishii M, Ito M, Sueta D, Oimatsu Y, Sakamoto K, Tsujita K, Kojima S, Nakagawa K, Hokimoto S and Ogawa H. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J Thromb Haemost, 2016; 14: 850-859","DOI":"10.1111\/jth.13256"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Arai H, Yamashita S, Yokote K, Araki E, Suganami H and Ishibashi S. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis, 2017; 261: 144-152","DOI":"10.1016\/j.atherosclerosis.2017.03.032"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kockx M, Gervois PP, Poulain P, Derudas B, Peters JM, Gonzalez FJ, Princen HM, Kooistra T and Staels B. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood, 1999; 93: 2991-2998","DOI":"10.1182\/blood.V93.9.2991.409k03_2991_2998"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yamashita S, Rizzo M, Su TC and Masuda D. Novel Selective PPAR\u03b1 Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis. Metabolites, 2023; 13","DOI":"10.3390\/metabo13050626"},{"key":"21","unstructured":"21) Montalescot G, Collet JP, Choussat R and Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J, 1998; 19 Suppl H: H11-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Heinrichy J and Assmann G. Fibrinogen and Cardiovascular Risk. Journal of Cardiovascular Risk, 1995; 2: 197-205","DOI":"10.1177\/174182679500200304"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kannel WB, Wolf PA, Castelli WP and D\u2019Agostino RB. Fibrinogen and Risk of Cardiovascular Disease: The Framingham Study. JAMA, 1987; 258: 1183-1186","DOI":"10.1001\/jama.1987.03400090067035"},{"key":"24","unstructured":"24) Behar S. Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention. Blood Coagul Fibrinolysis, 1999; 10 Suppl 1: S41-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Nakanishi N, Kaikita K, Ishii M, Kuyama N, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Kanazawa H, Hanatani S, Sueta D, Takashio S, Arima Y, Araki S, Usuku H, Nakamura T, Suzuki S, Yamamoto E, Soejimaa H, Matsushita K and Tsujita K. Hemodialysis-related low thrombogenicity measured by total thrombus-formation analysis system in patients undergoing percutaneous coronary intervention. Thromb Res, 2021; 200: 141-148","DOI":"10.1016\/j.thromres.2021.02.004"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Ishii M, Kaikita K, Mitsuse T, Nakanishi N, Oimatsu Y, Yamashita T, Nagamatsu S, Tabata N, Fujisue K, Sueta D, Takashio S, Arima Y, Sakamoto K, Yamamoto E and Tsujita K. Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation - The ATTRACTIVE-TTAS study. Int J Cardiol Heart Vasc, 2019; 23: 100346","DOI":"10.1016\/j.ijcha.2019.100346"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ishikawa T, Terai N, Igarashi T, Yamazaki S, Kobayashi T, Sato T, Iwanaga A, Sano T, Yokoyama J and Honma T. Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease. Clin Exp Hepatol, 2023; 9: 172-178","DOI":"10.5114\/ceh.2023.127813"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/6\/33_65984\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:30:44Z","timestamp":1780716644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/6\/33_65984\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65984","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"65984"}}